Key Documents

View All Documentation

G2295

Glimepiride

Name: Glimepiride
Brand: SIGMA

≥98% (HPLC), insulin secretagogue, solid

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₄H₃₄N₄O₅S

CAS Number:

93479-97-1

Molecular Weight:

490.62

UNSPSC Code:

12352200

PubChem Substance ID:

24895093

NACRES:

NA.77

MDL number:

MFCD00878417

Assay:

≥98% (HPLC)

Form:

solid

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

Glimepiride, ≥98% (HPLC), solid

Quality Level

100

assay

≥98% (HPLC)

form

solid

color

white

mp

212.2-214.5 °C

solubility

DMSO: >10 mg/mL

originator

Sanofi Aventis

storage temp.

room temp

SMILES string

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

InChI key

WIGIZIANZCJQQY-RUCARUNLSA-N

Gene Information

human ... ABCC8(6833), KCNJ1(3758), KCNJ11(3767)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecules

General description

Glimepiride is a class II biopharmaceutical second-generation sulfonylurea.

Application

Glimepiride has been used:

as a hypoglycemic drug to test its anti-diabetic functionality in human umbilical vein cells (HUVECs)
as a sulfonylurea ATP-sensitive potassium channel (K_ATP) channel inhibitor in breast cancer MDA-MB-231 cells
in glucose-stimulated insulin secretion (GSIS) assays of neonatal islet-like cell clusters (NICCs) to test its effect on insulin secretion

Glimepiride is currently used to treat type 2 diabetes.

Biochem/physiol Actions

Glimepiride is a potent blocker of cardiac K_ATP channels activated by pinacidil with an IC₅₀ of 6.8 nM.

Glimepiride reduces blood glucose levels by stimulating the pancreatic β cells to secrete insulin hormone. It interacts with a 65-kD protein associated with β cells.

Potent blocker of cardiac K_ATP channels.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

GHS08

signalword

Warning

hcodes

H361

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A REVIEW ARTICLE ON GLIMEPERIDE: AN ORAL HYPOGLYCAEMIC DRUG

Tiwari A, et al.

International Journal of Advanced Research , 4, 920-927 (2016)

Combination Therapy of Nifedipine and Sulphonylureas Exhibits a Mutual Antagonistic Effect on the Endothelial Cell Dysfunction Induced by Hyperglycemia Linked to Vascular Disease.

Li-Ping Wang et al.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 38(6), 2337-2347 (2016-05-21)

By inducing severe endothelial impairment, hypertension and diabetes are two leading causes of morbidity and mortality. Hypertensive patients with concomitant diabetes must take both antihypertensive and hypoglycaemic medications, for which there is a lack of experimental and clinical guidelines. This

Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy.

Mitsuyoshi Takahara et al.

Endocrine journal, 59(12), 1131-1136 (2012-08-02)

We retrospectively investigated the effect of adding dipeptidyl peptidase-4 (DPP-4) inhibitor and tapering sulfonylurea on blood glucose fluctuation in Asian patients with type 2 diabetes mellitus under basal-supported oral therapy (BOT). We recruited twenty-two consecutive Japanese patients with type 2

The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride.

Vladimer Darsalia et al.

Diabetes, 62(4), 1289-1296 (2012-12-05)

Type 2 diabetes is a strong risk factor for stroke. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes. The aim of this study was to determine the potential antistroke efficacy of linagliptin in type

Subsets of ATP-sensitive potassium channel (KATP) inhibitors increase gap junctional intercellular communication in metastatic cancer cell lines independent of SUR expression.

Thomas M Bodenstine et al.

FEBS letters, 586(1), 27-31 (2011-11-29)

Gap junctional intercellular communication (GJIC) regulates cellular homeostasis by propagating signaling molecules, exchanging cellular metabolites, and coupling electrical signals. In cancer, cells exhibit altered rates of GJIC which may play a role in neoplastic progression. K(ATP) channels help maintain membrane

View All Related Papers

Global Trade Item Number

SKU	GTIN
G2295-50MG	04061833628805
G2295-250MG	04061832574530

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service